Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Stevenson

Internal Medicine New Castle, IN Medical Doctor

NPI 1740376805 CMS profile 441695

152 Wittenbraker Ave, New Castle, IN 47362

Open in the dashboard

General payments

$9,302

514 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Stevenson of New Castle, IN is reported in the CMS Open Payments database as having received $9,302 across 514 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,688 103
2024 General $2,102 107
2023 General $1,440 94
2022 General $1,878 83
2021 General $465 6
2020 General $323 13
2019 General $1,406 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Stevenson
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robert Stevenson were reported at $1,688. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robert Stevenson Internal Medicine median Middle half National median
2019 $1,406 $159 $48–$570 $163
2020 $323 $119 $33–$402 $114
2021 $465 $135 $37–$521 $132
2022 $1,878 $141 $42–$496 $149
2023 $1,440 $149 $45–$519 $160
2024 $2,102 $154 $47–$537 $164
2025 $1,688 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,676 32 payments
  2. Novo Nordisk Inc $1,311 62 payments
  3. AbbVie, Inc. $1,239 95 payments
  4. Lilly USA, LLC $797 56 payments
  5. Pfizer Inc. $459 31 payments
  6. GlaxoSmithKline, LLC. $438 29 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $340 26 payments
  8. E.R. Squibb & Sons, L.L.C. $308 9 payments
  9. ITI, Inc. $292 20 payments
  10. Alnylam Pharmaceuticals Inc. $229 8 payments
  11. Other $2,214 146 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,293 512 payments
  2. Education $9 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,099 21 payments
  2. Ozempic $730 38 payments
  3. RYBELSUS $669 31 payments
  4. AIRSUPRA $635 6 payments
  5. BREZTRI $517 7 payments
  6. MOUNJARO $422 28 payments
  7. VRAYLAR Neuroscience $367 27 payments
  8. VRAYLAR Neuroscience $359 26 payments
  9. ELIQUIS $308 9 payments
  10. JARDIANCE $302 22 payments
  11. Other $6,859 452 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 147 drugs

Part D claims

11,893

Median for Internal Medicine: 777

Drug cost

$1,278,708

Median for Internal Medicine: $73,373

Branded share of claims

22.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hetlioz Tasimelteon Brand 15 $335,707
Jardiance Empagliflozin Brand 166 $215,499
Ozempic Semaglutide Brand 98 $112,064
Mounjaro Tirzepatide Brand 55 $72,438
Januvia Sitagliptin Phosphate Brand 57 $70,023
Eliquis Apixaban Brand 69 $67,225
Farxiga Dapagliflozin Propanediol Brand 35 $41,454
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 211 $33,769
Trulicity Dulaglutide Brand 14 $20,574
Linzess Linaclotide Brand 21 $20,525

The 10 drugs with the highest cost, of 147 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $328
$328 — —
AREXVY
  • GlaxoSmithKline, LLC. $185
$185 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $143
$143 — —
MOUNJARO
  • Lilly USA, LLC $129
$129 55 —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

514 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record